FGF 23 regulates renal sodium handling and blood pressure
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Fibroblast growth factor‐23 ( FGF 23) is a bone‐derived hormone regulating renal phosphate reabsorption and vitamin D synthesis in renal proximal tubules. Here, we show that FGF 23 directly regulates the membrane abundance of the Na + :Cl − co‐transporter NCC in distal renal tubules by a signaling mechanism involving the FGF receptor/αKlotho complex, extracellular signal‐regulated kinase 1/2 ( ERK 1/2), serum/glucocorticoid‐regulated kinase 1 ( SGK 1), and with‐no lysine kinase‐4 ( WNK 4). Renal sodium (Na + ) reabsorption and distal tubular membrane expression of NCC are reduced in mouse models of Fgf23 and α Klotho deficiency. Conversely, gain of FGF 23 function by injection of wild‐type mice with recombinant FGF 23 or by elevated circulating levels of endogenous Fgf23 in Hyp mice increases distal tubular Na + uptake and membrane abundance of NCC , leading to volume expansion, hypertension, and heart hypertrophy in a αKlotho and dietary Na + ‐dependent fashion. The NCC inhibitor chlorothiazide abrogates FGF 23‐induced volume expansion and heart hypertrophy. Our findings suggest that FGF 23 is a key regulator of renal Na + reabsorption and plasma volume, and may explain the association of FGF 23 with cardiovascular risk in chronic kidney disease patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · cited 2×
“Klotho is a single-pass transmembrane protein which is mainly expressed in the kidney in renal proximal and distal convoluted tubules, in parathyroid glands, but also in other tissues such as the brain choroid plexus (Kuro-o et al , 1997; Hu et al , 2010; Andrukhova et al , 2012).”
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027 · cited 2×
“…cardiovascular risk factors such as left ventricular hypertrophy, vascular calcifications, and mortality in CKD patients (Juppner et al , 2010; Faul et al , 2011), suggesting that FGF23 may have additional biological functions which cannot be explained by the known effects of FGF23 on mineral…”
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Klotho converts canonical FGF receptor into a specific receptor for FGF23
Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., & Yamashita, T. (2006) · Nature · doi:10.1038/nature05315 · Cited by 1,850
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,596
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K. E., Evans, W. E., O'Riordan, J. L. H., Speer, M. C., Econs, M. J., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. M. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,528
Human Hypertension Caused by Mutations in WNK Kinases
Wilson, F. H., Disse-Nicodème, S., Choate, K. A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D. V., Lipkin, G. W., Achard, J.-M., et al. (2001) · Science · doi:10.1126/science.1062844 · Cited by 1,487
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101545198 · Cited by 1,457
Dhingra, R. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.9.879 · Cited by 861 · cited 1×
“Hyperphosphatemia is a major risk factor for vascular calcification in patients with chronic renal disease (Scialla et al , 2013) and cardiovascular disease in normal subjects (Dhingra et al , 2007).”
Cited by
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
The Klotho proteins in health and disease
Kuro-o, M. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0078-3 · Cited by 707
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho
Yamada, S., & Giachelli, C. M. (2017) · Bone · doi:10.1016/j.bone.2016.11.012 · Cited by 316
FGF23 and its role in X-linked hypophosphatemia-related morbidity
Beck-Nielsen, S. S., Mughal, Z., Haffner, D., Nilsson, O., Levtchenko, E., Ariceta, G., de Lucas Collantes, C., Schnabel, D., Jandhyala, R., & Mäkitie, O. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1014-8 · Cited by 278
FGF23 signalling and physiology
Ho, B. B., & Bergwitz, C. (2021) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0178 · Cited by 180
“Expression of NCC and thus sodium reabsorption is decreased in an FGF23deficient mouse model, and conversely injection of FGF23 into WT mice results in increased sodium reabsorption and volume expansion, an effect not observed with inhibition of ERK1/2 or SGK1 or following the injection of FGF23 into KL-null mice (And…”
BackgroundLi, D.-J., Fu, H., Zhao, T., Ni, M., & Shen, F.-M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.009 · Cited by 92
“Moreover, FGF23 increases distal renal tubular Na uptake and leads to volume expansion [14], and underlies some metabolic action of leptin [15].”
BackgroundKuro-o, M. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy126 · Cited by 80
Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs
He, T., Qin, L., Chen, S., Huo, S., Li, J., Zhang, F., Yi, W., Mei, Y., & Xiao, G. (2025) · Bone Research · doi:10.1038/s41413-025-00424-1 · Cited by 58
Humalda, J. K., Yeung, S. M. H., Geleijnse, J. M., Gijsbers, L., Riphagen, I. J., Hoorn, E. J., Rotmans, J. I., Vogt, L., Navis, G., Bakker, S. J. L., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa359 · Cited by 26
“A comprehensive study in mice showed that FGF23 directly regulates sodium homeostasis by increasing sodiumchloride cotransporter membrane abundance in the distal convoluted tubule, suggesting cross-talk between FGF23 and sodium homeostasis (61).”
BackgroundHu, J.-W., Wang, Y., Chu, C., & Mu, J.-J. (2018) · Medical Science Monitor · doi:10.12659/msm.906489 · Cited by 17
Metadata
- Authors
- Andrukhova, O., Slavic, S., Smorodchenko, A., Zeitz, U., Shalhoub, V., Lanske, B., Pohl, E. E., & Erben, R. G.
- Venue
- EMBO Molecular Medicine
- Published
- 2014-05-05
- Volume
- 6
- Issue
- 6
- Pages
- 744-759
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2167995070
- Cited by
- 320
- References
- 57
- FWCI
- 19.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.